1. Home
  2. GNPX vs SINT Comparison

GNPX vs SINT Comparison

Compare GNPX & SINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$0.58

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Logo SiNtx Technologies Inc.

SINT

SiNtx Technologies Inc.

HOLD

Current Price

$2.11

Market Cap

11.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNPX
SINT
Founded
2009
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
11.1M
IPO Year
2017
2007

Fundamental Metrics

Financial Performance
Metric
GNPX
SINT
Price
$0.58
$2.11
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$11.00
AVG Volume (30 Days)
373.7K
42.5K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
59.45
EPS
N/A
N/A
Revenue
N/A
$1,018,000.00
Revenue This Year
N/A
$30.26
Revenue Next Year
N/A
$413.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$1.86
52 Week High
$12.97
$6.78

Technical Indicators

Market Signals
Indicator
GNPX
SINT
Relative Strength Index (RSI) 36.89 44.85
Support Level $0.17 $1.93
Resistance Level $2.12 $2.46
Average True Range (ATR) 0.06 0.17
MACD -0.00 0.01
Stochastic Oscillator 42.85 56.82

Price Performance

Historical Comparison
GNPX
SINT

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

About SINT SiNtx Technologies Inc.

SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.

Share on Social Networks: